Abstract:OBJECTIVE:To detect the levels of serum C-C chemokine ligand 19 (CCL19) in patients with systemic lupus erythematosus (SLE) and to evaluate the correlation between CCL19 expression and clinical features and laboratory parameters, trying to reveal the possible role of CCL19 in the pathogenesis of systemic lupus erythematosus.METHODS:The levels of serum CCL19 were measured by enzyme linked immunosorbent assay (ELISA) in 90 patients with SLE and 30 healthy controls. These SLE patients included 75 patients who received treatment with glucocorticoids and disease-modifying anti-rheumatic drug (DMARD) and 15 patients without therapy. The frequencies of peripheral blood B cells and the B cell subsets were assessed in the patients with SLE by flow cytometry. The correlation between the clinical data, laboratory parameters, B cell subset frequencies and serum CCL19 levels were analyzed. Indepen-dent samples t test, paired t test, Pearson and Spearman correlation were used for statistical analyses.RESULTS:The levels of CCL19 were markedly higher in the SLE patients without therapy and the patients with therapy than in the health controls[(596.25±409.19) ng/L and (422.90±395.84) ng/L vs. (157.79±125.23) ng/L, all P<0.001]. Serum CCL19 levels in the SLE patients without therapy were higher than the SLE patients who accepted glucocorticoids and DMARD treatment (P<0.05). The levels of serum CCL19 were positively correlated with anti-double stranded deoxyribonucleic acid (dsDNA), anti-nucleosome antibody (AnuA), IgA, IgG and IgM (r=0.38, P=0.007; r=0.332, P=0.029; r=0.519, P=0.007; r=0.461, P=0.018, respectively). Serum CCL19 levels in the SLE patients with photosensitivity, arthritis and secondary Sjögren's syndrome were higher than the SLE patients without photosensitivity, arthritis and secondary Sjögren's syndrome, respectively [(562.25±399.12) ng/L, (565.6±435.24) ng/L and (694.9±531.02) ng/L vs. (394.7±281.42) ng/L, (385.90±325.33) ng/L and (424.8±305.46) ng/L, all P<0.05]. The levels of serum CCL19 were positively correlated with the percentage of CD27-B cells and CD27-IgD-double-negative memory B cells (r=0.519, P=0.007; r=0.461, P=0.018, respectively). However, the levels of serum CCL19 were negatively correlated with the percentage of CD27+ memory B cells and CD27+IgD- switched memory B cells (r=-0.433, P=0.027; r=-0.616, P=0.001, respectively).CONCLUSION:The increased serum CCL19 levels in SLE patients were associated with the production of autoantibodies, and CCL19 might be involved in the pathogenesis of SLE by disturbing the homeostasis of B cell subsets.

[Changes of Serum BAFF and IL-21 Levels in Patients with Systemic Lupus Erythematosus and Their Clinical Significance].

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

Peripheral CD24hi CD27+ CD19+ B Cells Subset As a Potential Biomarker in Naïve Systemic Lupus Erythematosus.

Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients.

Abnormal Expression of Cd43 in Patients with Systemic Lupus Erythematosus and Its Clinical Significance

Correlation of Serum B Cell Activating Factor with Disease Activity in Patients with Systemic Lupus Erythematosus

Abnormal Expression of BAFF and Its Receptors in Peripheral Blood and Skin Lesions from Systemic Lupus Erythematosus Patients

The Serum Levels and Significance of B Cell Activating Factor in Some Frequent Rheumatic Ddisease

Levels of Soluble Interleukin-2 Receptor and Clinical Significance in Patients with Systemic Lupus Erythematosus

Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity

Increased Interleukin 21 and Follicular Helper T-like Cells and Reduced Interleukin 10+ B Cells in Patients with New-onset Systemic Lupus Erythematosus

BAFF system expression in double negative 2, activated naïve and activated memory B cells in systemic lupus erythematosus

Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients

Levels of serum IL-18 and IL-34 in patients with lupus nephritis and their significance

[Increased Serum C-C Chemokine Ligand 19 Levels Correlated with B Cell Abnormalities in Systemic Lupus Erythematosus].

Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus

Change and Significance of Interleukin-18 in Patients with Systemic Lupus Erythematosus

[Serum IL-21 Level in Patients with Primary Sjogren's Syndrome and Clinical Significance of IL-21].

High Interleukin 21 Levels in Patients with Systemic Lupus Erythematosus: Association with Clinical Variables and rs2221903 Polymorphism

Serum Level of Leptin in Patients with Systemic Lupus Erythematosus:Correlated with Lupus Activity